Reuters logo
BRIEF-Supernus Pharmaceuticals ‍continues to expect enrollment through mid-2018 for SPN-810 phase III clinical trials​
September 18, 2017 / 8:20 PM / a month ago

BRIEF-Supernus Pharmaceuticals ‍continues to expect enrollment through mid-2018 for SPN-810 phase III clinical trials​

Sept 18 (Reuters) - Supernus Pharmaceuticals Inc

* Supernus provides update on SPN-810 phase III clinical trials

* Supernus Pharmaceuticals Inc - ‍Continue to expect enrollment through mid-2018 for SPN-810 phase III clinical trials​

* Supernus Pharmaceuticals Inc - Based on predefined criteria for dropping a dose arm, lower dose of 18 mg will be eliminated

* Supernus - Patients to be randomized to either 36 mg dose arm or placebo until predetermined no. Of patients are enrolled without changing size of trials​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below